DEPDC5 and tuberous sclerosis: In vitro functional studies indicate that DEPDC5 is an inhibitor of mTORC1 signalling, suggesting that DEPDC5-associated epilepsy may result from aberrant mTORC1 signalling, as is the case in tuberous sclerosis patients who often have epilepsy.